Combination treatment before surgery for locally advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of drugs given before surgery for locally advanced prostate cancer. The goal is to see if giving these drugs first helps shrink the tumor and improves outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 to 75.
- You must have prostate cancer that has not spread to distant organs, but is locally advanced (tumor has grown beyond the prostate or spread to nearby lymph nodes).
- You must be scheduled for surgery to remove the prostate (radical prostatectomy).
- You should be generally well and able to care for yourself (ECOG score 0-1).
- You must not have had any prior treatment for prostate cancer (like surgery, radiation, chemotherapy, or hormone therapy).
- You must not have cancer spread to bones, liver, brain, or other organs, and you must not need strong pain medications for cancer pain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
This trial tests a combination of drugs given before prostate removal surgery. The goal is to see if this treatment can shrink or slow high-risk prostate cancer.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This study tests whether giving the drug darolutamide (with or without standard hormone therapy) before surgery helps shrink high-risk prostate cancer and reduce the chance of it coming back. If you qualify, you would receive the study treatment for a few months before your planned prostate removal surgery.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.